Category: 1217599-13-7piperazines

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1217599-13-7,(R)-1-Boc-2-Isobutylpiperazine,as a common compound, the synthetic route is as follows.

(R)-tert-but l 4-(6-chloro-5-cyano-3-fluoropyridin-2-yl)-2-isobutylpiperazine-l-carboxylateA mixture of tert-butyl (2R)-2-isobutylpiperazine-l-carboxylate (515 mg, 2.13 mmol), 2,6- dichloro-5-fluoro-pyridine-3-carbonitrile (405.9 mg, 2.13 mmol) and DIPEA (274.6 mg, 370.1 mu, 2.13 mmol) in NMP was heated at 130 C for 20 minutes under microwave conditions. After this time, the reaction mixture was allowed to cool to ambient temperature and diluted with EtOAc and water. The organic layer was separated and washed with brine, dried ( a2S04), filtered and concentrated in vacuo. The crude mixture was purified by column chromatography (ISCO Companion, 120 g column, eluting with EtO Ac/Petroleum ether) to give the sub title compound (629.9 mg, 75% Yield). XH NMR (400 MHz, CDC13) delta 7.37 (d, J= 12.6 Hz, 1H), 4.55 – 4.23 (m, 3H), 4.1 1 (q, J= 7.2 Hz, 1H), 3.23 (dd, J= 13.4, 3.6 Hz, 1H), 3.08 (d, J= 9.4 Hz, 2H), 1.64 – 1.52 (m, 1H), 1.50 – 1.28 (m, 1 1H), 0.93 (d, J= 6.5 Hz, 6H).

1217599-13-7, As the paragraph descriping shows that 1217599-13-7 is playing an increasingly important role.

Reference£º
Patent; VERTEX PHARMACEUTICALS INCORPORATED; JIMENEZ, Juan-Miguel; GOLEC, Julian, M.C.; SETTIMO, Luca; FRAYSSE, Damien; BRENCHLEY, Guy; BOYALL, Dean; TWIN, Heather; YOUNG, Stephen; MILLER, Andrew, W.; DAVIS, Christopher, John; WO2011/94283; (2011); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics

1217599-13-7, (R)-1-Boc-2-Isobutylpiperazine is a piperazines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a vial containing (R) -tert-butyl 2-isobutylpiperazine-1-carboxylate (17-a) (50.8 mg, 0.210 mmol, commerically available from Matrix Scientific, Cairo, Egypt) , were added compound 10-d (48.3 mg, 0.220 mmol) , DMF (2.0 mL) and DIEA (100 mul, 0.57 mmol) . The mixture was stirred at RT for 19 h. The mixture was then filtered and purified by preparative, reverse-phase HPLC (eluting with ACN/water with 0.1%TFA) to afford (R) -tert-butyl 4- (5-cyano-2- (1-methyl-1H-pyrazol-4-yl) pyrimidin-4-yl) -2-isobutylpiperazine-1-carboxylate (17-b) as the TFA salt. MS (ESI) Calc?d for C22H32N7O2[M+1]+, 426; found, 426., 1217599-13-7

The synthetic route of 1217599-13-7 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; MERCK SHARP & DOHME CORP.; MCGOWAN, Meredeth A.; KATZ, Jason D.; CHRISTOPHER, Matthew; ZHOU, Hua; WITTER, David James; LI, Chaomin; LAMPE, John; METHOT, Joey L.; ACHAB, Abdelghani A.; XU, Shimin; FRADERA, Xavier; (123 pag.)WO2019/119206; (2019); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics